Ontology highlight
ABSTRACT: Background
Most lethal prostate cancers progress from relapse of aggressive primary disease. Recently, the most significant advances in survival benefit from systemic therapy have come from moving the administration of therapy to an earlier disease state. There is movement toward using biomarkers from the intraprostatic index lesion to guide early systemic therapy.Objective
To determine the genomic heterogeneity, including the heterogeneity of predictive biomarkers, within the index focus of treatment-naïve prostate cancer.Design, setting, and participants
Ten patients with treatment-naïve prostate cancer underwent prostatectomy. DNA was extracted from 70 spatially distinct regions of the 10 index foci.Outcome measurements and statistical analysis
Single nuc
SUBMITTER: VanderWeele DJ
PROVIDER: S-EPMC6586528 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature